{
    "organizations": [],
    "uuid": "9096904d2e2ee8af841806e7b18ead7fe62d9ef0",
    "author": "",
    "url": "https://www.reuters.com/article/brief-bristol-myers-squibb-says-cancer-d/brief-bristol-myers-squibb-says-cancer-drug-combo-reduces-death-risk-by-42-pct-idUSFWN1RT0N8",
    "ord_in_thread": 0,
    "title": "BRIEF-Bristol-Myers Squibb Says Cancer Drug Combo Reduces Death Risk By 42 Pct",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 16, 2018 / 1:33 PM / Updated 11 minutes ago BRIEF-Bristol-Myers Squibb Says Cancer Drug Combo Reduces Death Risk By 42 Pct Reuters Staff 1 Min Read \nApril 16 (Reuters) - Bristol-Myers Squibb Co: \n* OPDIVO PLUS LOW-DOSE YERVOY COMBINATION REDUCES THE RISK OF PROGRESSION OR DEATH BY 42% VERSUS CHEMOTHERAPY IN FIRST-LINE LUNG CANCER PATIENTS WITH HIGH TUMOR MUTATIONAL BURDEN (TMB) \n* BRISTOL-MYERS SQUIBB - IN STUDY, YERVOY COMBINATION DEMONSTRATED SUPERIOR BENEFIT FOR CO-PRIMARY ENDPOINT OF PFS VERSUS CHEMOTHERAPY Source text for Eikon: Further company coverage:",
    "published": "2018-04-16T16:33:00.000+03:00",
    "crawled": "2018-04-16T16:53:22.039+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "squibb",
        "say",
        "cancer",
        "drug",
        "combo",
        "reduces",
        "death",
        "risk",
        "pct",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "squibb",
        "co",
        "opdivo",
        "plus",
        "yervoy",
        "combination",
        "reduces",
        "risk",
        "progression",
        "death",
        "versus",
        "chemotherapy",
        "lung",
        "cancer",
        "patient",
        "high",
        "tumor",
        "mutational",
        "burden",
        "tmb",
        "squibb",
        "study",
        "yervoy",
        "combination",
        "demonstrated",
        "superior",
        "benefit",
        "endpoint",
        "pfs",
        "versus",
        "chemotherapy",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}